Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

Eli Lilly (LLY) reported better than expected earnings for the second quarter Thursday. But disappointing results of its much-awaited oral pill GLP-1 sent its stock down in early trading. The stock is ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight by an average of 12% after 72 weeks.

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion. Over ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment. A popular ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

That drug is orforglipron, Eli Lilly’s GLP-1 drug that patients administer orally rather than through an injectable pen. The results of orforglipron’s Phase 3 Food and Drug Administration (FDA ...